Novo Nordisk

News

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

Sales & Marketing

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

News

Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version.

News

Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.

News

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.